Bio-Thera(SH:688177) Xin Lang Cai Jing·2025-11-17 02:13Core Viewpoint - Baiotai's stock price has shown a year-to-date increase of 34.93%, but recent trading indicates a decline in the short term, with a notable drop of 21.45% over the past 60 days [2] Company Overview - Baiotai Biopharmaceutical Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on July 28, 2003, with its listing date on February 21, 2020 [2] - The company focuses on the research and production of innovative drugs and biosimilars, with its main business revenue composition being: 91.90% from drug sales, 6.55% from licensing, 0.90% from contract manufacturing, and 0.65% from technical services [2] Financial Performance - For the period from January to September 2025, Baiotai achieved an operating income of 684 million yuan, representing a year-on-year growth of 17.57%, while the net profit attributable to shareholders was -224 million yuan, reflecting a year-on-year increase of 38.72% [2] Stock Market Activity - As of November 17, Baiotai's stock price was 26.15 yuan per share, with a trading volume of 13.01 million yuan and a turnover rate of 0.12%, resulting in a total market capitalization of 10.828 billion yuan [1] - The net outflow of main funds was 120,900 yuan, with large single purchases amounting to 588,900 yuan (4.53% of total) and sales of 709,800 yuan (5.45% of total) [1] Shareholder Information - As of September 30, 2025, the number of Baiotai's shareholders was 9,397, a decrease of 0.89% from the previous period, with an average of 44,065 circulating shares per person, an increase of 0.89% [2] - Hong Kong Central Clearing Limited is the tenth largest circulating shareholder, holding 6.0247 million shares as a new shareholder [2]